ATS GUIDELINES Bundle

INSIDE ▶ Introduction ▶ Recommendations ▶ Tables ▶ Figures Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1467089

Contents of this Issue

Navigation

Page 12 of 25

13 ILDs with cysts and/or airspace filling Sarcoidosis Exposure related Langerhan's cell histiocytosis (LCH) Lympho- proliferative LAM Medication Others Radiation Illicit drugs Post infectious Respiratory bronchiolitis interstitial lung disease (RB-ILD) c Pulmonary alveolar proteinosis (PAP) a e committee acknowledges that eosinophilic pneumonia of unknown cause was not included in the IIP classification. b Myositis includes polymyositis/dermatomyositis (PM/DM) anti-synthetase syndrome which may be amyopathic. c While RB-ILD is acknowledged to be a consequence of exposure to cigarette smoke in virtually all patients with RB- ILD, RB-ILD and DIP oen coexist. Although DIP is also related to exposure to cigarette smoke in majority of patients, DIP is also seen in some patients with CTD, without exposure to cigarette smoke, and without a known cause. HP Occupational • Asbestosis • Silicosis • Coal miner • Berylliosis and many others

Articles in this issue

view archives of ATS GUIDELINES Bundle - INSIDE ▶ Introduction ▶ Recommendations ▶ Tables ▶ Figures Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis